INVITED SPEAKER (sorted by the alphabet)

Bermingham, Sean

Sean joined PSE in 2000 and was PSE’s Global Head of Consulting for 8 years before forming the Formulated Products business in 2010.  As head of this division, he is responsible for strategic business development, software development and services delivery for the pharma, food, consumer good, specialty & agrochemical industries. Sean is a leading figure in the development and adoption of mechanistic model-based tools for increasing R&D efficiency and managing risk in areas ranging from clinical trials to tech transfer and operations.  He is the driver behind QbD 2.0, which focuses on improving the efficiency of QbD by reintroducing the “sound science” element of the original QbD definition. He is one of the founders of the Systems-based Pharmaceutics Alliance (2013-present) with Eli Lilly, GSK, Pfizer, Roche and Sanofi.  Sean was also the lead for the £20.4m ADDoPT “Digital Design” Project (2015-2019) with partners including AZ, BMS, GSK & Pfizer. Sean is a Chemical Engineer with an MSc and a PhD from Delft University of Technology and an Executive MBA from Imperial College London.

Bernkop-Schnürch, Andreas

Andreas Bernkop-Schnürch is serving as the Head of the Department of Pharmaceutical Technology at the University of Innsbruck. He is a leading researcher and inventor in the field of drug delivery, nanotechnology and biomaterials. He is author of >450 research articles and reviews and founder of MucoBiomer GmbH (meanwhile part of Croma Holding), ThioMatrix GmbH ( and Green River Polymers GmbH (

Bolzinger, Marie-Alexandrine

Pr. Marie-Alexandrine Bolzinger is a pharmacist and full professor in pharmaceutical technology at ISPB (Faculté de Pharmacie de Lyon, France). Her current research in LAGEPP (Laboratory of Automatic Control, Chemical and Pharmaceutical Engineering, UMR-CNRS 5007) is focused on dosage forms for the topical route, with special focus on emulsions (Pickering emulsions), microemulsions and nano-microparticle formulations for topical delivery. She is also involved in the development of biopharmaceutical methods to follow the skin delivery of drugs in vitro but also interactions between skin components and ingredients. Other research interests and activities cover the production of innovative systems to decontaminate the skin from toxic warfare agents. 

Brandl, Ferdinand

Head of laboratory, Development Pharma Solutions, BASF SE

Dr. Ferdinand Brandl studied pharmacy in Regensburg, Germany. After receiving his PhD in pharmaceutical technology, he was a postdoctoral fellow at the Massachusetts Institute of Technology, Cambridge, MA, USA. Before joining BASF SE, he was a research associate at the Department of Pharmaceutical Technology, University of Regensburg, Germany. Since 2016, he is part of R&D for pharmaceutical excipients and drug formulations at BASF SE.

Couvreur, Patrick

Patrick COUVREUR is Emeritus Professor at Paris-Saclay University, member of the Académie des Sciences and holder of the chair of “Innovations Technologiques” (2009-2010) at the prestigious « Collège de France ». Prof COUVREUR’s contributions in the field of drug delivery and nanomedicine are highly recognized around the world with 600 publications (Google Scholar H-index 128 and 71,000 citations). He founded three start-up companies (Bioalliance, entering the stock market in 2005, Medsqual and Squal Pharma) and developed an anticancer nanomedicine reaching phase III clinical trial. His scientific contribution is recognized by numerous international and national awards.

Apart from the Académie des Sciences, he is also appointed as a member of 3 other academies in France (Engineering, Medicine and Pharmacy) and a foreign member of the US National Academies of Engineering and Medicine, of the Royal Academy of Medicine in Belgium and of the Royal Academy of Pharmacy in Spain. By a decree of the President of the French Republic, Patrick Couvreur is appointed as “Chevalier de la Légion d’Honneur”.

de Silva, Nalin

K. M. Nalin de Silva is a Senior Professor of Chemistry at the University of Colombo, Sri Lanka. He obtained his B.Sc. (Chemistry, First Class) from the University of Colombo, Sri Lanka and Ph.D. from the University of Cambridge, UK. He has gained postdoctoral experience from University of Cambridge and Louisiana State University, USA. He won the Presidential Research Award for 10 consecutive years and a National Research Award presented by National Science Foundation (NSF), Sri Lanka. He was also named ‘Young Scientist of the Year’ in 2004 by The World Academy of Science (TWAS) and NSF.  He was a member of the National Nanotechnology Committee and the Chairman of the National Nanotechnology Research Panel at NSF. He was also a member of the committee at NSF for drafting the National Nanotechnology Policy of Sri Lanka.

He also served as the Chairman of National Basic Sciences Research Committee at NSF and presently Chairing the National committee on Technology. He has published over 100 manuscripts and four patents in USPTO. His main research focus areas are drug delivery, bionanotechnology, water purification, textiles and apparel and natural resources. He is the recipient of Professor P.P.G.L. Siriwardena Gold Medal Oration Award and Devanathan Memorial Award for research presented by the Institute of Chemistry, Ceylon. He has active collaborations with School of Pharmacy, University College London, UK and National Chung Hsing University of Taiwan. He was the Director of Career Guidance Unit of University of Colombo during 2002 - 2005. He was also a Visiting Professor at Sultan Qaboos University, Sultanate of Oman.

Descamps, Marc

Marc Descamps is Emeritus Professor of Solid state Physics at the University of Lille (France). He has created the Group “Molecular and Therapeutic Materials” in the CNRS lab. UMR 8207 in Lille. He led the European INTERREG network IDEA (“Improving Drug Efficacy and Availability”). He is the author of more than 180 publications in international journals and he has collaborated with several large pharmaceutical companies. His research interests include: phase transitions in molecular materials, disordered crystals, molecular glasses and studies of the structural and dynamic properties of molecular solids by a variety of physicochemical techniques. His current research activity focuses on the phase and state transformations of molecular solids induced by milling with a particular interest on the implication of the amorphous state. In 2016 he has edited the book "Disordered Pharmaceutical Materials" (Wiley) and the special issue of the Advanced Drug Delivery Review (Vol 100) "Amorphous Pharmaceutical Solids".

Some details and list of recent publications can be found at the following address:

Donnelly, Ryan

Professor Ryan Donnelly holds the Chair in Pharmaceutical Technology at Queen’s University Belfast and is Director of the university’s new interdisciplinary research programme Materials & Advanced Technologies for Healthcare, comprising 58 academics from Pharmacy, Chemistry & Chemical Engineering, Mechanical & Aerospace Engineering, Biological Sciences, Nursing and Medicine. His personal research is centred on design and physicochemical characterisation of advanced polymeric drug delivery systems for transdermal and intradermal drug delivery, with a strong emphasis on improving patient outcomes. He is currently developing a range of novel microneedle technologies through independent research, but also in collaboration with several major pharma partners. He has obtained substantial research funding and authored over 700 peer-reviewed publications, including 4 patent applications, 6 textbooks, 23 book chapters and approximately 200 full papers.

He has been an invited speaker at numerous national and international conferences. Professor Donnelly is Editor-in-Chief of Recent Patents on Drug Delivery & Formulation and Europe/Africa Editor of Drug Delivery & Translational Research. He has won Evonik’s Resomer Award (2018), the Controlled Release Society’s Young Investigator Award (2016), BBSRC Innovator of the Year and the American Association of Pharmaceutical Scientists Pharmaceutical Research Meritorious Manuscript Award (2013), the GSK Emerging Scientist Award (2012) and the Royal Pharmaceutical Society’s Science Award (2011). 

Edirisinghe, Mohan

Professor Mohan Edirisinghe FREng holds the established Bonfield Chair of Biomaterials in the Department of Mechanical Engineering at University College London (UCL) and has served as a University of London professor for over 20 years. He was appointed to this UCL chair in December 2005 and prior to this he was Professor of Materials at Queen Mary University of London. He has actively pursued advanced materials processing, forming and manufacturing research, for over 25 years publishing over 450 journal papers with a H-index of 61 and over 12,600 citations (Source: Google Scholar, September 2019). In addition, his research has led to many inventions and patents and he has also delivered over a 100 keynote/invited lectures at many different international conferences and meetings worldwide, particularly in the USA (major recent meetings include: TMS, MS&T and MRS). He has supervised over 200 researchers, graduating 100 doctoral students (39 to date at UCL), and has been awarded grants to the value of over £25 million, with 43 UK Research Council grants including two Platform Grants which have given him the opportunity to adventurously explore novel avenues of forming and manufacture of advanced materials for application in key areas such as healthcare. His research has won many prizes including the Royal Society Brian Mercer (Innovation) Feasibility Award an unprecedented three times (2005, 2009 and 2013), the 2010 Materials Science Venture Prize and the 2012 Presidents Prize of the UK Biomaterials Society to recognise outstanding contributions to the biomaterials field. In 2017 he was the recipient of The Royal Academy of Engineering Armourers & Brasiers prize for excellence in Materials Engineering and the Premier IOM3 Chapman Medal for his distinguished research in the field of biomedical materials.

Fries, Lennart

Graduated from Hamburg University of Technology, Germany, in 2008, diploma in process engineering. Obtained PhD with honors from same university in 2012 on the topic of Discrete particle modeling of fluid bed agglomeration of amorphous food powders. Joined Nestlé Research Lausanne, Switzerland in 2012 as Research Scientist, working on powder reconstitution, flowability, fine grinding and gentle drying processes of food powders. Appointed key project manager in 2017. Promotion to group leader Science & Technology Catalyzer at Nestlé R&D Beijing, China, in 2019.

Gazzaniga, Andrea

Andrea Gazzaniga is a Full Professor and Dean of the School of Pharmacy at the University of Milan. He is the author of more than 200 publications, including research papers, reviews and patents, and of over 500 conference presentations. His main research interests concern the design and manufacturing of oral drug delivery systems, particularly for prolonged, pulsatile and colonic release. He is a Fellow of the American Association of Pharmaceutical Scientists (AAPS), member of the editorial boards of leading journals in the field, consultant for regulatory agencies and served as an Official Expert (Group 12-Galenical Products) for European Pharmacopoeia.

Jörg, Susanne

Susanne Jörg joined Lonza, Switzerland, in 2006 as Head of Pharmaceutical Development, Drug Product Services. Her team is responsible for formulation and process development for customers' projects and related analytical testing, manufacturing of preclinical drug product supplies, process transfer to the GMP manufacturing site, and primary packaging and device functionality testing.

Prior to joining Lonza, Susanne worked for 10 years in leadership roles at Novartis, most recently as Group Head Early Phase Pharmaceutical Development. She was involved into the development of Cosentyx as well as several product IND/IMPD submissions of monoclonal antibodies, recombinant protein, fusion proteins, bioconjugates, antibody fragments, nanobodies, and antibody-drug-conjugates for parenterals for various administration routes. Susanne studied pharmacy and holds a Ph.D from the Ludwig Maximillians University, Munich, Germany. In collaboration with Merck KGaA, Darmstadt (DE), she developed liquid high-concentration mAb formulations, and supported the registration filing of Erbitux®.

Kabanov, Alexander

Alexander Kabanov, a Distinguished Professor at the Eshelman School of Pharmacy, UNC-Chapel Hill, director of Center for Nanotechnology in Drug Delivery and Carolina Institute for Nanomedicine. He pioneered the use of polymeric micelles, DNA/polycation complexes, nanogels, macrophage carriers and exosomes for delivery of drugs, nucleic acids and polypeptides and invented the first polymeric micelle technology for cancer drug delivery to enter the clinical trials. Published over 300 scientific papers, holds 35 US patents and co-founded pharmaceutical companies to develop products based on polymeric micelles. Elected member of Academia Europaea, fellow of CRS, NAI and AIMBE, director-at-large CRS.

Kendal, Pitt

Kendal Pitt is a Senior  Technical Director and a Senior Fellow in Pharma Supply Chain Technical based at Ware, UK.     He is a Fellow of the Royal Pharmaceutical Society (FRPharmS) and an Eminent Fellow of the Academy of Pharmaceutical Sciences and has worked in the Pharmaceutical Industry for over 30 years in both R&D and Production.   He has headed groups in both the United States and Great Britain and led project teams responsible for the successful filing and launch of tablets, capsules and freeze-dried dosage forms.   

Khinast, Johannes

Prof.  Johannes G. Khinast is the head of the Institute for Process and Particle Engineering at the Graz University of Technology and the scientific director of the Research Center Pharmaceutical Engineering. He received his Ph.D. in the area of particle technology in 1995 from the Graz University of Technology. He was then a post doctoral fellow at the University of Houston with Prof. Dan Luss. In 1998 Prof. Khinast joined Rutgers University (New Jersey, USA) as an assistant professor, where he was granted early tenure in 2003. In 2005 Prof. Khinast was selected as a Marie Curie Chair of the EU, and in 2006 he was offered a professorship at the Graz University of Technology.

Prof. Khinast has received significant funding for his work in process simulation, pharmaceutical process engineering and particle technology in the order of more than 80 million Euros from various sources. He has supervised more than 40 Ph.D. students and PostDocs and his publication record encompasses over 240 peer-reviewed publications and 8 book chapters. He also holds 10 patents in the area of pharmaceutical manufacturing.

Lammers, Twan

Twan Lammers obtained a DSc degree in Radiation Oncology from Heidelberg University in 2008 and a PhD degree in Pharmaceutics from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at the Institute for Experimental Molecular Imaging at RWTH Aachen University Clinic. In 2014, he was promoted to full professor at the faculty of medicine at RWTH Aachen. He has published over 200 research articles and reviews, and has received several scholarships and awards. He is associate editor for Europe for the Journal of Controlled Release, and serves on the editorial board of multiple additional journals. His primary research interests include drug targeting to tumors, image-guided drug delivery and tumor-targeted combination therapies.

Leane, Michael

Michael Leane is a Senior Principal Scientist with Bristol-Myers Squibb.  He graduated with a Pharmacy degree from Trinity College Dublin and has a PhD in Advanced Drug Delivery from the University of Nottingham.  His current role at BMS is within drug product development where he specialises in the optimisation of API particle properties to facilitate drug product manufacture.  

He is a former director of the UK Academy of Pharmaceutical Sciences (APS) and is on the scientific advisory board for the Irish SSPC.  He has authored and co-authored a number of publications around amorphous formulation development and novel characterisation techniques.  He is co-lead of an APS-sponsored working group aiming to establish a Manufacturing Classification System for oral solid dosage forms.  This initiative developed from an APS conference in 2013 and has grown through the publication of two peer-reviewed position papers and interaction with other international pharmaceutical science bodies such as the AAPS, APV and APSTJ.

Leuenberger, Hans

Hans Leuenberger wrote a PhD thesis in nuclear physics. Then, he worked at Sandoz Pharma (today: Novartis). In 1982 he became a full professor in Pharmaceutical Technology at the University of Basel. He received numerous awards (see: awards gallery). He is member of the American Association of Pharmaceutical Scientists, the Royal Academy of Pharmacy (Spain), the Russian Academy of Engineering and Honorary Member of the Swiss Academy of Engineering Sciences. As professor emeritus he became in 2018 a member of the Adjunct Faculty of the College of Pharmacy of the University of Florida, Orlando Campus at Lake Nona (USA).

Lyon, David

David Lyon, Ph.D., Sr. Fellow, Global Research working at Lonza—Bend, Bend, Oregon USA. David Lyon received his B.S. in Chemistry from Western Washington University and Ph.D. in Inorganic Chemistry from the University of Oregon.  Following a Post-Doctoral stint at the California Institute of Technology, David joined Bend Research as a Research Chemist.  During his tenure at Bend Research he held positions of increasing responsibility culminating in the role of Senior Vice President, Research prior to the company’s acquisition by Capsugel and, subsequently, Lonza.  He currently serves as a Sr. Fellow advising internal and external collaborations in bioavailability enhancement technologies, inhaled therapies, highly potent compounds and biomanufacturing.  

Mignet, Nathalie

Dr Nathalie MIGNET is Director of Research at the National Center for Scientific Research in France. She is the head of the Laboratory Chemical and Biological Technologies for Health located at Université de Paris in France.

After a PhD in France in organic chemistry, Dr Mignet was hired by the company Lynx Therapeutics in San Francisco. She then joined the University of Sheffield in UK. In 1998, she was hired by the French biotech company Capsulis to work on onion-based nanoparticles called spherulites. She joined the CNRS as a research Scientist in 2000 to work on non-viral gene delivery. Since then, she expanded her domain of interest from drug delivery systems to nanomedicine designed for triggered delivery or imaging.

With her team, she is interested in nanomedicine for delivery or imaging going from fundamental to preclinical studies. 

She is also the founder and the president of the French Society for Nanomedecine, SFNano. 

Moissl-Eichinger, Christine

Christine Moissl-Eichinger is a university professor at the Medical University of Graz, Austria, who is dedicated to microbiome research and education of young scientists. Before accepting her professorship position in 2014, Christine worked seven years as a junior group leader at the Archaea Center at the University of Regensburg, Germany, and before that, held a PostDoc position at Caltech/ NASA Jet Propulsion Laboratory in Pasadena, USA. 

She is a microbial ecologist by training, with a passion for special, possibly overlooked microorganisms which have a high impact on the microbiome and the host system. She is member of the European Academy of Sciences and Arts and organizer of the Theodor Escherich Symposium on Medical Microbiome Research in Austria. Christine is living with her family (husband and two daughters) in Styria and together they actively enjoy the wonderful landscape.

Mooney, David

David Mooney is the Pinkas Family Professor of Bioengineering in the Harvard School of Engineering and Applied Sciences, and a Core Faculty Member of the Wyss Institute. He received his B.S. in Chemical Engineering from the University of Wisconsin, and Ph.D. in Chemical Engineering from MIT.  His laboratory designs biomaterials to make cell and protein therapies effective and practical approaches to treat disease. He is a member of the National Academy of Engineering, the National Academy of Medicine, and the National Academy of Inventors.  He has won numerous awards, including the Clemson Award from the SFB, MERIT award from the NIH, Distinguished Scientist Award from the IADR, Phi Beta Kappa Prize for Excellence in Undergraduate Teaching, and the Everett Mendelsohn Excellence in Mentoring Award from Harvard College.  His inventions have been licensed by numerous companies, leading to commercialized products, and he is active on industrial scientific advisory boards.

Nolli, Maria Luisa

Maria Luisa is co-founder and CEO of NCNbio, a company focused on the Industrial Technology Transfer in biotechnology.  Maria Luisa  was the founder and former CEO of Areta International , a biotech company  focused on the development and production of innovative biodrugs and advanced therapy medicinal products and she was the site manager of the company from 2000 to 2012. Maria Luisa  is also a co-founder of two university  spin off, Hope and Skin Squared, respectively with the  Milano University and Modena University.  Maria Luisa brought to all these companies  her multi year experience in cell biology and immunology, matured as scientist and team leader in multinational companies of  Dow Chemical as Dow Lepetit , Merrell Dow, Marion Merrell Dow e Hoechst Marion Roussel. Maria Luisa (ex alumna of Collegio Ghislieri in Pavia), received her doctoral degree in Biological Sciences from the University of Pavia (1977). She had a doctoral fellow at the  Université Libre de Bruxelles, and a Post Doctoral Fellow at the Istituto di Medicina del Lavoro, University of Pavia and at the  International Institute of Genetics and Biophysics (CNR Naples)  From 2008 Maria Luisa is member of the board of Assobiotec and delegate to Europabio board.  From June 2014 is member of the board of AFI (Associazione Farmaceutici dell’Industria) as representative of the biotech sector and AIRI (Associazione Italiana Ricerca Industriale) as expert of  red biotech   From 2015 to 2018 Maria Luisa was the president of Women & Technology Association and  today she is member of the Board. In 2007 she received the “Premio Piazza Mercanti” from the Milan Chamber of Commerce. In 2009 is one of the 100 profiles of the volume dedicated to Milan of "The protagonists: women who make Italy" In 2012 she received the “Premio “Rosa Camuna” from Regione Lombadia for innovative enterpreneuship She was professor at the University of Milano Bicocca (2001-2008) and Bari (2004-2011) and from February 2016  she is professor at Pavia University of Industrial Biochemistry course. Maria Luisa is author a and co-author of more than 60 publications and 11 patents.

O’Driscoll, Caitriona

Caitriona O’Driscoll is Professor and Chair of Pharmaceutics in the School of Pharmacy in UCC. She completed her PhD studies in Pharmaceutical Sciences in Trinity College Dublin (TCD) and undertook a sabbatical in the Department of Pharmaceutical Chemistry at the University of Kansas, USA. She was a senior lecturer in the School of Pharmacy at TCD prior to her appointment to UCC in 2003. She is a Board member of the Health Products Regulatory Authority, and the Critical Path Institute. She is a founding member and Chair of Regulatory Science Ireland.

Professor O’Driscoll’s research interests are translational in nature and include formulation of nano-sized drug delivery constructs, which remain stable during processing and storage, and are safe and effective for use by patients. Candidate drugs include biopharmaceuticals, peptide/proteins, nucleic acids and poorly water-soluble compounds. Delivery systems of interest are; lipid-based vehicles and non-viral gene delivery systems employing modified cyclodextrins, nanoparticles and receptor-ligand mediated targeting.

Pauli, Victoria

Victoria Pauli works as Formulation Project Lead in the Novartis Continuous Manufacturing (CM) Unit, focusing on product and process development for solid oral dosage forms, using continuous manufacturing technology. Prior to starting in that position, she spent three years as a PhD Student in the CM Unit, working on process control strategy development and implementation, in cooperation with Professor Dr. Dr.h.c. Kleinebudde from the University of Düsseldorf. Initially, she studied Pharmaceutical Sciences (M.Sc.) and Pharmacy at the LMU Munich, where she first started to be interested in PAT techniques and CM process control.

Rantanen, Jukka

Jukka Rantanen is professor of pharmaceutical technology and engineering at the Department of Pharmacy (University of Copenhagen). He received his Ph.D. from the University of Helsinki in 2001, completed postdoctoral visit at the Department of Industrial and Physical Pharmacy (Purdue University, USA) in 2003, and joined the faculty at the University of Copenhagen in 2006 as a full professor. Jukka Rantanen was appointed 2017 as a guest professor at Shenyang Pharmaceutical University, China. He is a recipient of the APV (International Association of Pharmaceutical Technology) “Research Award for Outstanding Achievements in the Pharmaceutical Sciences” in 2016. 

Roberts, Clive

Clive has led many major programmes of research and has published over 300 peer reviewed papers across a number of pharmaceutical science disciplines. He founded the successful Nottingham Nano and Microtechnology Centre in 2005. Nanotechnology has also served as a great platform to support public engagement including leading several major public exhibitions and roadshows directly engaging over 30,000 members of the public. More recently his research has included 3D printing of medicines, with major support from EPSRC, AstraZeenca and GSK amongst others. Some of the first tablets produced from this work were exhibited in the London Science Museum and Manchester Industrial Science Museum.

Clive received the UK Academy of Pharmaceutical Sciences Medal Award in 2019 for his work on 3D printing. Translation to market is an important part of Clive’s work. He founded eminate Ltd, a £6.5M TSB funded Nottingham University company which rapidly translated products to the market including the multi-award winning salt reduction product, SodaLoTM. Clive was also a co-founder and Technical Development Director of Molecular Profiles Ltd a recipient of two Queens Award for Enterprise. Molecular Profiles Ltd became part of Juniper Pharma Inc in 2013 and was recently purchased by Catalent Inc.

Roberts, Kevin

He is currently Brotherton Professor of Chemical Engineering at the University of Leeds in the UK, Director of the EPSRC’s Centre for Doctoral Training in Complex Particulate Products and Processes and Director of the Centre for the Digital Design of Drug Products.

His research interests centre on molecule-centred particle science and engineering and particular focus areas include:

  • Solution-state, solid-state, surface and interfacial chemistry of molecular materials including molecular- and synthonic- (intermolecular) centred modelling techniques.
  • Process analytical techniques (PAT) for understanding, monitoring and controlling crystallisation processes including the use of synchrotron radiation techniques for in-situ studies.
  • Crystallisation processes kinetics and their scale-up from laboratory to manufacturing including characterisation of the underpinning inter-relationship between structure, properties, processing and performance.
  • Digital Quality by Design (dQbD) tools and workflows for the design of structured products and their associated manufacturing processes.

His research work encompasses both fundamental and applied research, the latter in collaboration with the pharmaceuticals, specialities, fine chemicals, and nutritional products sectors.

Schneid, Stefan

Stefan Schneid is currently a laboratory head in the formulation development department at Bayer in Wuppertal, where he develops formulations and processes for NBEs and NCEs, including antibodies, ADCs and peptides, from pre-clinical stage up to process validation. Previously Dr. Schneid worked as R&D Manager at Syntacoll GmbH where he was responsible for the development of novel formulations and analytical methods for biodegradable implants. Until 2010, he was a post-doctoral research fellow in the Freeze Drying Focus Group at the University of Erlangen. Stefan Schneid holds a Ph.D. in Pharmaceutics and a degree of Pharmacy from the University of Munich. 

Schrader, Michael

Michael Schrader is the CEO of Vaxess, an NIH and VC-backed company bringing healthcare out of the clinic and into patients’ lives with the MIMIX Smart Release platform. MIMIX combines ease of administration with dramatic efficacy enhancements enabled by the "mimicry" of natural infections. The company has a pipeline of immunotherapies and vaccines, both in-house as well as through partnerships. Prior to Vaxess, Michael spent time at Google and Honda where he helped bring a range of products to market and earned fifteen patents. Michael received his B.S. in Mechanical Engineering from Purdue University and his M.B.A. from Harvard.

Schwendeman, Steve

Steve Schwendeman is the Ara G. Paul Professor and Chair of Pharmaceutical Sciences and Professor of Biomedical Engineering at the University of Michigan Biointerfaces Institute.  He is also Associate Editor of the Journal of Controlled Release since 2007.  He received his B.S.E. in Chemical Engineering in 1986 and his Ph.D. in Pharmaceutics in 1992 from the University of Michigan.  He was an NIH postdoctoral fellow at M.I.T. until 1995.  He received the CRS Young Investigator Award in 2002 and a CRS Best paper award in 2010.  He is a Fellow of both CRS and AAPS.  He has co-authored > 110 publications, trained > 25 PhD and 12 postdoctoral students, delivered > 110 invited lectures, consulted for > 25 companies, published > 140 abstracts and has 8 issued and several pending patents.  His principal contribution to science involves the theory and application of microencapsulation, stabilization, and controlled release of bioactive agents of all sizes with/in poly(lactic-co-glycolic acid) delivery systems.  More recently his lab has investigated buccal, nasal, and pulmonary delivery of hydrophobic drugs, vaccine antigens and nitric oxide.  He is currently funded by NIH, US FDA, large corporations and private foundations.

Sznitman, Josué

Josué Sznitman is a Swiss, French and Israeli national. Sznitman graduated from MIT (2002), followed by a Dr. Sc. (2008) from ETH Zurich. In 2008, Sznitman joined the U Pennsylvania as a Postdoctoral Fellow and moved to Princeton University as a Lecturer and Research Associate. He joined the Department of Biomedical Engineering at the Technion in 2010 as a tenure-track Assistant Professor and was promoted to Associate Professor with tenure in 2016. Sznitman currently serves as Associate Chair for Undergraduate Studies in the Department of Biomedical Engineering and is the Director of the Norman Seiden Graduate Program in Nanoscience & Nanotechnology. As a researcher, he directs the Technion Biofluids Laboratory. Sznitman was awarded the Young Investigator Award (2015) by the International Society of Aerosols in Medicine (ISAM) for a researcher under 40 and most recently the 2018 Emerging Scientist Award in Drug Delivery to the Lungs (Aerosol Society, UK).

Touitou, Elka

Professor Elka Touitou is an internationally recognized authority in the field of drug delivery and design of new technologies for nasal, transdermal and cannabinoid new products. She has been a Visiting Professor at Universities in Europe and Asia. She is the instructor of numerous graduate students at the Hebrew University and abroad. She has served as a Director in the Board of CRS and she is a CRS Fellow. Elka is the recipient of the Jorge Heller Outstanding Paper Award, the Kaye Award for Innovation and is honored as one of leader innovators at the Hebrew University. She has broad experience in collaborating with the pharmaceutical industry serving in their Advisory Board. Elka has more than 100 scientific publications including original research, reviews, book chapters and co-editor of two books and is the inventor of international granted patents. 

Tosi, Giovanni

Born in 1977 (March, 2nd) in Bologna, Italy, Prof. Tosi got his degree in Pharmacy in 2002 with 110/110.  He got his PhD in Pharmaceutical Sciences in 2005 at the University of Modena and Reggio Emilia, Italy.  Since November 2005, Prof. Giovanni Tosi has been researcher in the scientific field of Pharmaceutical Technology at the University of Modena and Reggio Emili and since 2015, he is associate professor in the same field.  He got ASN certificate for Full professor in 2017.

He has been Coordinator of "Applied Technology" curricula for the PhD school in Health Products, Research associate at NEST, Istituto Nanoscienze-CNR, Pisa (Italy), member of the Committee for Research of University of Modena and Reggio Emilia and scientific delegate for international cooperation and coordinator of UNIMORE Nanomedicine Platform since 2017. He is deputy-chair of Nanotherapeutic WG in European Technology Platform for Nanomedicine.

He is or has been involved in numerous activities as referee for national and international grants, principal investigator or participant to numerous partnerships in international and national projects focused on both brain delivery and cancer targeting. He is member of Te.Far.T.I. (Centro di ricerca sulle Tecnologie Farmaceutiche Tradizionali ed Innovative, UNIMORE), ADRITELF (associazione docenti e ricercatori italiani di tecnologie e legislazione farmaceutiche), Controlled Release Society Italian Chapter (CRS Italy) and American Nano Society. 

Globally, prof. Tosi is author or co-author of more than 90 publications in international journals (and gave over 200 presentations (invited speaker, oral presentations and posters) in international and national congresses mainly focused drug delivery to the brain.

Van der Walle, Chris

Chris van der Walle obtained his PhD in peptide chemistry from King’s College London, where he was subsequently awarded a Maplethorpe Fellowship. He moved to the University of Oxford to study cell-matrix interactions before taking up a lectureship at the University of Bath and later a Readership at the University of Strathclyde, implementing a new Master’s course in Drug Delivery. In 2012, he joined the Formulation Sciences group at MedImmune and then the Drug Delivery group in AstraZeneca as Director-Fellow. He is currently Head of Formulation of Cell & Gene Therapy at GlaxoSmithKline. He has published over 90 research articles, reviews and book chapters, in fields including cell adhesion, supramolecular chemistry, peptide and protein formulation, surface adsorption and particulate drug delivery systems.

Wauthoz, Nathalie

Nathalie Wauthoz, PharmD, PhD supervises researches in the Unit of Pharmaceutics and Biopharmaceutics of ULB in respiratory (lung and nasal) drug delivery and in oncology (lung cancer and glioblastoma). She is also co-founder of the InhaTarget Therapeutics, a spin-off company of the ULB dedicated to the development of innovative dry powders for inhalation. She is also Lecturer at ULB and had supervised/is supervising 10 PhD students until now. She published 40 peer-reviewed publications in international journals in pharmaceutical sciences and medicinal field, 2 chapters of book, 5 patents and more than 50 posters and presentations in scientific meetings. 

Nathalie Wauthoz, email:
Unit of Pharmaceutics and Biopharmaceutics, Faculty of Pharmacy,
Université Libre de Bruxelles (ULB)
Website of the spin-off company :

Yoo, Jaedeok

Dr. Jae Yoo is serving as Chief Technology Officer for Aprecia Pharmaceuticals, LLC since August 2018.  His 3DP journey started at MIT in the early 1990's where he developed and used an inkjet printing based 3DP process to fabricate advanced ceramic materials with compositional gradient.  He explored and demonstrated a wide range of pharmaceutical and biomedical applications of 3DP while working for Therics, Inc., a VC backed company that licensed the technology from MIT. In 2003, he co-founded Aprecia Pharmaceuticals and headed its research and engineering efforts to develop a high-speed, additive manufacturing process suitable for cGMP operation. His work set the foundation for first ever FDA approval of a 3D printed pharmaceutical product, SPRITAM®, manufactured and marketed by Aprecia.  He was part of GlaxoSmithKline (2014-2018) and explored automation for R&D productivity gain and evaluated platform capabilities for Advanced Manufacturing Technology initiative.  He is a co-inventor of many US and international patents on additive manufacturing of pharmaceutical products and medical devices.  Prior to his graduate work at MIT, he studied Metallurgical Engineering and Materials Science at Carnegie Mellon University. He holds MBA from Wharton School at University of Pennsylvania.